Pahlkotter Maranda, Digney Bradley W, Yu Allen T, Schmidt Lee, Cohen Noah A, Sarpel Umut, Lambert Laura
Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Jordan Valley Medical Center, Salt Lake City, Utah, USA.
J Surg Oncol. 2024 Oct;130(5):1130-1138. doi: 10.1002/jso.27802. Epub 2024 Nov 3.
Peritoneal carcinomatosis carries a grim survival prognosis with complications ranging from the physical to the psychological. Cytoreductive surgery and infusion of heated intraperitoneal chemotherapy have evolved to become a commonly used treatment option in the multi-modal management of peritoneal carcinomatosis. Here, we examine the origins of surgery over a century ago as a potential cure for peritoneal carcinomatosis and how it has evolved with our knowledge of the disease to its present state. The origin of chemotherapy is similarly described as well as its progressive application in regional therapy, guided by the ongoing development of new agents, better understanding of peritoneal physiology, and improved systemic treatment. We show how these modalities began to be used in tandem, and standardized, leading to randomized trials and better understanding of the possibilities and limitations of treatment. Finally, we discuss the current status of patient selection for cytoreduction and future directions of intraperitoneal chemotherapy.
腹膜癌病的生存预后严峻,会引发从身体到心理等一系列并发症。减瘤手术和热灌注腹腔化疗已发展成为腹膜癌病多模式治疗中常用的治疗选择。在此,我们探究一个多世纪前手术作为腹膜癌病潜在治愈方法的起源,以及它如何随着我们对该疾病的认知发展到目前的状态。同样会描述化疗的起源及其在区域治疗中的逐步应用,这是由新型药物的不断研发、对腹膜生理学的深入理解以及系统性治疗的改善所推动的。我们展示了这些治疗方式如何开始联合使用并实现标准化,从而促成了随机试验,并加深了对治疗可能性和局限性的理解。最后,我们讨论减瘤手术患者选择的现状以及腹腔化疗的未来发展方向。